Prostate Cell News Volume 9.34 | Sep 7 2018

TOP STORY

Roswell Park Team Identifies Possible Cause of Resistance to Prostate Cancer Treatment

A collaborative research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target for one of the deadliest forms of cancer among men. [Press release from the Roswell Park Comprehensive Cancer Center discussing online prepublication in Nature Communications] Press Release | Full Article

(Ranked by impact factor of the journal)

Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer

The lead molecule KCI807 primarily affected a subset of androgen receptor (AR) target growth genes selectively suppressing AR-dependent growth of prostate cancer cell lines with a better inhibitory profile than enzalutamide. KCI807 also inhibited in vivo growth of castration/enzalutamide-resistant cell line-derived and patient-derived tumor xenografts. [Clin Cancer Res] Abstract | Full Article

Reduced Arginyltransferase 1 Is a Driver and a Potential Prognostic Indicator of Prostate Cancer Metastasis

Researchers found that metastatic prostate cancer cell lines had a reduced level of arginyltransferase 1 (Ate1) protein compared to non-metastatic cell lines, and that a depletion of Ate1 drove prostate cancer cells towards more aggressive pro-metastatic phenotypes without affecting proliferation rates. [Oncogene] Abstract

Histone Demethylase KDM7A Controls Androgen Receptor Activity and Tumor Growth in Prostate Cancer

Scientists found that a KDM7A-deficient cell line showed lower androgen receptor downstream gene expression compared to a control cell. Increased H3K27 di-methylation was observed in KDM7A knock-down LNCaP stable cell. Treatment with KDM7A inhibitor, TC-E 5002, reduced proliferation and induced apoptosis of prostate cancer cells. [Int J Cancer] Abstract

Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide

A library of differently functionalized naphthalene diimides (NDIs) was screened for their ability to stabilize androgen receptor (AR) G-quadruplexes: the core-extended NDI stood out as the most promising ligand. Seven synergistically interacted with enzalutamide, an inhibitor of AR signaling used in second-line therapies. [J Med Chem] Abstract

The Putative Tumor Suppressor miR-1-3p Modulates Prostate Cancer Cell Aggressiveness by Repressing E2F5 and PFTK1

Investigators found that miR-1-3p was significantly downregulated in advanced prostate cancer (PCa) tissues and cell lines. miR-1-3p could directly target the mRNA 3′- untranslated region of two central cell cycle genes, E2F5 and PFTK1, and could suppress their mRNA and protein expression. Knockdown of E2F5 and PFTK1 mimicked the tumor-suppressive effects of miR-1-3p overexpression on PCa progression. [J Exp Clin Cancer Res] Full Article

Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells

Betulinic acid (BA) reduced androgen receptor protein stability and mRNA expression, making it an attractive agent for castration-resistant prostate cancer. Scientists identified multiple and specific deubiquitinases (DUBs) inhibited by BA either in prostate cancer cells or using recombinant DUBs. [Sci Rep] Full Article

NPRL2 Enhances Autophagy and the Resistance to Everolimus in Castration-Resistant Prostate Cancer

Nitrogen permease regulator-like 2 (NPRL2) over-expression promoted proliferation and resistance to everolimus (EVS), and NPRL2 silencing inhibited proliferation and enhanced sensitivity to EVS in PC3 and enzalutamide-resistant LNCaP cells. NPRL2-silencing increased the activity of mTOR signaling, and autophagy attenuation induced by NPRL2-silencing in EVS-treated castration-resistant prostate cancer cells was associated with the increase of apoptosis. [Prostate] Abstract

High Mobility Group A2 (HMGA2) Promotes EMT via MAPK Pathway in Prostate Cancer

Both wild-type and truncated high mobility group A2 increased levels of phospho-ERK, and treatment with U0126, a MAPK inhibitor, antagonized wild-type HMGA2-mediated epithelial-mesenchymal transition (EMT) and cell migration, but did not affect truncated HMGA2-mediated cell proliferation or migration. [Biochem Biophys Res Commun] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors

The authors focus on the interaction among the androgen receptors, estrogen receptors, and liver X receptors in prostate homeostasis and their putative pharmacological modulations in parallel to the patients’ support. [Int J Mol Sci] Full Article | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

$12 Million to Combat Prostate Cancer

The Morrison Government and Movember Foundation are teaming up to combat prostate cancer by investing $12 million into ground-breaking new research aimed at reversing the significant number of deaths caused by the disease. [Greg Hunt MP] Press Release

Minomic Secures Key Patent in the United States and China

Minomic International Ltd announced the grant of its patent ‘Cell surface prostate cancer antigen for diagnosis’ in the key global markets of the United States of America and China. [Minomic International Ltd] Press Release

Peer Reviewers Unmasked: Largest Global Survey Reveals Trends

Scientists in developed countries provide nearly three times as many peer reviews per paper submitted as researchers in emerging nations, according to the largest ever survey of the practice. [Nature News] Editorial

AACR Apologizes for Delays in Retracting Papers

The American Association for Cancer Research (AACR) has issued retractions, corrections, or editor’s notes for a handful papers across five of its journals and is sorry for the time it’s taken to do so, according to a statement published in Cancer Research. [The Scientist] Editorial

FDA Official Says Trump’s New Limits on Hiring Foreign Scientists Makes It Harder to Attract Top Talent

The Trump administration’s restrictions on hiring foreign scientists are making it more difficult for the agency to attract top scientific talent, a top FDA official said. “[The policy] definitely has created an additional challenge, I think, for us,” said Melanie Keller, the FDA’s acting associate commissioner for scientific and clinical recruitment. [STAT News] Editorial

NEW 2019 Urological Society of Australia and New Zealand (USANZ) Meeting
April 13-16, 2019
Brisbane, Australia

Visit our events page to see a complete list of events in the community.

NEW Assistant Professor – Basic and Translational Cancer Research (Texas Tech University Health Sciences Center)

Assistant/Associate Faculty Position – Prostate Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Prostate Cancer Progression (Aarhus University)

Postdoctoral Position – Translational Cancer Research (University of California, Davis)

Postdoctoral Fellow/Research Scientist – Prostate Cancer (Università della Svizzera italiana)

Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic)

Senior Research Scientist – Prostate Cancer Research (University of California, San Francisco)

Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Assistant or Associate Professor – Prostate Cancer (Lerner Research Institute of the Cleveland Clinic)

Postdoctoral Position – Tumor Ecosystem Research (University of Zurich)

Postdoctoral Fellow – Prostate Cancer Metastasis Research (Oregon Health & Science University)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.